[Breaking] Celltrion Announces Phase 3 Clinical Trial Results of 'Rekkirona'... "Efficacy and Safety Proven"
![[Breaking] Celltrion Announces Phase 3 Clinical Trial Results of 'Rekkirona'... "Efficacy and Safety Proven"](http://www.asiae.co.kr/news/img_view.htm?img=2020120210173242872_1606871853.jpg)
[Asia Economy Reporter Chunhee Lee] Celltrion announced on the 14th that it has proven the efficacy and safety of its COVID-19 antibody treatment 'Rekkirona' by releasing the topline results of the global Phase 3 clinical trial.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
